SCHEMBL19862704

SCHEMBL19862704

COC(=O)C(Cc1ccc(C#N)c(F)c1)c1ccc(OC)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.49
ESR2 Q92731 1/20 0.49
S1PR3 Q99500 5/20 0.47
S1PR1 P21453 1/20 0.47
ACACB O00763 1/20 0.42
CYP11B1 P15538 2/20 0.41
CYP11B2 P19099 2/20 0.41
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40
TUBA3C P0DPH7 1/20 0.40
STAT3 P40763 1/20 0.40
TUBA1B P68363 1/20 0.40
TUBA4A P68366 1/20 0.40
TUBB4B P68371 1/20 0.40
TUBB3 Q13509 1/20 0.40
TUBB2A Q13885 1/20 0.40
TUBB8 Q3ZCM7 1/20 0.40
TUBA3E Q6PEY2 1/20 0.40
TUBA1A Q71U36 1/20 0.40
TUBA1C Q9BQE3 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25211567 0.80 CACNA1H (0.43) S1PR3ACACBCACNA1HCTSD
SCHEMBL19685162 0.77 S1PR3 (0.48) S1PR3S1PR1CYP11B1CYP11B2TUBB4A
SCHEMBL7743300 0.76 CPB2 (0.48) CYP11B1CYP11B2CACNA1H
SCHEMBL17222600 0.76 S1PR3 (0.55) S1PR3S1PR1CYP11B1CYP11B2TUBB4A
SCHEMBL2403690 0.74 ESR1 (0.60) ESR1ESR2NPC1RAB9ASMN1; SMN2
SCHEMBL23494950 0.73 ESR1 (0.63) ESR1ESR2MEN1KMT2ASMN1; SMN2
SCHEMBL5365140 0.72 S1PR3 (0.46) S1PR3S1PR1CYP11B1CYP11B2MAOB
SCHEMBL9278424 0.72 ESR1 (0.54) ESR1ESR2TUBB4ATUBBTUBA3C
SCHEMBL9896903 0.72 ESR1 (0.73) ESR1ESR2MEN1KMT2ALDHA
SCHEMBL5388435 0.71 SMN1; SMN2 (0.49) S1PR3S1PR1CYP11B1CYP11B2TUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018031658-A1 TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS CELGENE CORPORATION (US) 2018-02-15 WO disclosed